Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central nervous method, conolidine modulates alternate molecular targets. A Science Innovations study found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://luisy022buh6.wikilowdown.com/user